Phase I/II trial of Allocetra™ cell therapy for knee osteoarthritis: clinical evidence of response to modulation of inflammation
Abstract format and assignment number: Poster POS0684
Presenting author: E. Galamidi (Israel)
Date: Wednesday, 11 June 2025, 15:30 – 16:30
This study evaluated the safety and efficacy of intra-articular Allocetra™ for symptomatic knee osteoarthritis (OA). In a Phase I study, Allocetra™ showed a favourable safety profile and significant pain reduction (52.4%) and improved functionality (45.4%) in OA patients at 3 months, with 80% responding. This promising initial efficacy supports progression to a randomised Phase II trial.
Buffered soluble alendronate treatment preventing rebound following denosumab discontinuation in erosive hand OA: a randomized trial
Abstract format and assignment number: Poster POS0667
Presenting author: T. Vanhaverbeke (Belgium)
Date: Wednesday, 11 June 2025, 15:30 – 16:30
This study investigated whether buffered soluble alendronate could prevent bone loss rebound in erosive hand osteoarthritis (HOA) patients after denosumab discontinuation. A 48-week alendronate regimen proved significantly more effective than a 24-week regimen at curbing increases in bone turnover markers and preventing spine BMD loss. However, alendronate did not halt new erosions or prevent worsening hand pain. These findings support using a 48-week alendronate protocol for safer denosumab discontinuation in HOA.
Comparison of the efficacy of 12-month romosozumab followed by 24-month denosumab versus 36-month denosumab or risedronate for glucocorticoid-induced osteoporosis in patients with rheumatic diseases; a randomized prospective study
Abstract format and assignment number: Oral Presentation OP0049
Presenting author: M. Kawazoe (Japan)
Date: Wednesday, 11 June 2025, 16:30 – 16:40
This study assessed the long-term efficacy of a 12-month romosozumab (ROMO) followed by a 24-month denosumab (DMAb) sequence (ROMO-DMAb) on bone mineral density (BMD) in glucocorticoid-induced osteoporosis (GIOP) patients, compared to DMAb or bisphosphonates (BP) alone. After 36 months, ROMO-DMAb led to the greatest lumbar spine BMD increase (11.3%), significantly outperforming DMAb (9.4%) and BP (2.1%). The regimen was also found to be safe, with no significant differences in fracture incidence or adverse events.
The effect of weight loss and glucagon-like peptide-1 receptor agonist on structural changes in knee osteoarthritis: secondary analysis of the randomised, placebo-controlled LOSEIT trial
Abstract format and assignment number: Oral presentation OP0223
Presenting author: M. W. Brejnebøl (Denmark)
Date: Thursday, 12 June 2025, 10:40 – 10:50
This study assessed whether liraglutide, combined with weight loss, could slow structural knee osteoarthritis (OA) progression. While liraglutide led to greater weight loss and a minor mmJSW increase, this difference was not statistically significant compared to placebo. Further research with more potent GLP-1 RAs is suggested.
Romosozumab: analysis of safety and differential effectiveness in specific subgroups: patients with rheumatoid arthritis, diabetes mellitus, and corticosteroids-induced osteoporosis
Abstract format and assignment number: Poster POS1330
Presenting author: M. S. Moreno Garcia (Spain)
Date: Saturday, 14 June 2025, 10:15 – 11:45
This real-world study assessed romosozumab’s (ROMO) effectiveness and safety over 12 months in 216 highly fracture-risk women with osteoporosis, examining its impact on various subgroups. ROMO significantly increased lumbar spine BMD (8.76%) and femur BMD (5.65%). These improvements were observed across all subgroups except for patients with diabetes mellitus, who showed smaller increases. The treatment was well-tolerated with no major cardiovascular events reported.
Juan C Sarmiento-Monroy, MD, MSc
Juan C. is a Rheumatologist and clinical research fellow at the Hospital Clinic of Barcelona. His main research interests include the validation of biomarkers in RA-ILD, the application of ultrasound in systemic autoimmune rheumatic diseases, crystal arthropathies, and the development of digital tools for patients with SLE.
Juan C. is a member of the EMEUNET Education Sub-Committee.